Combined effects of 17-DMAG and TNF on cells through a mechanism related to the NF-kappaB pathway

Zhuling Qu*, He Dong*, Xiaolin Xu, Wei Feng and Xuanlong Yi

Abstract

Objective: The tumor necrosis factor (TNF) and the cellular NF-κB pathway protein IKKβ play important roles in various cellular processes such as cell proliferation, survival, differentiation, and apoptosis. A heat shock protein 90 inhibitor, 17-DMAG, can induce apoptosis of some tumor cells. This study is to determine the combined effects of 17-DMAG and TNF on malignant cells and the related mechanisms.

Methods: We have determined effects of 17-DMAG, an Hsp90 inhibitor, and TNF treatments on the small cell lung cancer cell line (MS-1), the adenocarcinoma cell line (A549), the squamous-cell carcinoma cell line (LK-2), and the normal human bronchial epithelium cell line (NuLi-1) by using the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay. To determine if 17-DMAG inhibit the expression of IKKβ in the normal human NuLi-1 cells, and the malignant MS-1, A549, and LK-2 cells, immunoblotting assays and luciferase assays were performed.

Results: It was found that the combined treatments resulted in synergistic killing of malignant cells, which was confirmed by the apoptosis determination using a fluorescence microscopic assay following staining of the drug-treated cells with Hoescht 33258. The immunoblotting results indicated that the synergistic killing due to 17-DMAG and TNF treatments may be related to the decreases in IKKβ levels in the presence of 17-DMAG.

Conclusions: The results suggest that combination of 17-DMAG and TNF treatments might be useful for treating malignancies upon further study in the further.

Virtual slides: The virtual slide(s) for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/vs/2041198513886824

Keywords: 17-DMAG, IKKβ, TNF, NF-κB Pathway

Introduction

Heat shock proteins (Hsps) are a group of chaperones that are important in maintaining stability and function of their client proteins. Heat shock protein 90 (Hsp90) regulates stability, degradation, translation, and function of its client proteins, via an ATP-regulated mechanism [1]. Unlike other Hsps, only approximately 200 cellular proteins are determined to be clients of Hsp90 [2-4]. Hsp90 inhibitors, such as 17-DMAG, are a group of small molecules that bind to the ATP-binding pocket of the Hsp90 dimers [5,6]. By competing with ATP, 17-DMAG can inhibit the protein chaperoning activity of Hsp90, resulting in misfolding of cellular client proteins such as the tyrosine kinase v-Src, the serine/threonine kinase Raf, mutant p53 proteins, the glucocorticoid receptor, and the androgen receptor HER2, resulting in protein destabilization and degradation, usually mediated by the proteosomal pathway [7]. A number of Hsp90 clients are involved in tumor developments [7]. In addition, the binding affinity of Hsp90 inhibitors to the ATP-binding pocket of Hsp90 are 10-fold higher in tumor cells than in normal cells [8]. Therefore, Hsp90 inhibitors are promising therapeutic reagent for treating malignant cells.
The tumor necrosis factor (TNF) plays important roles in various cellular processes such as cell proliferation, survival, differentiation, and apoptosis [9]. Since TNF can induce apoptosis of cells, it may be a potential therapeutic agent to treat cells. However, TNF induces multiple pathways including cell proliferation and survival processes that may facilitate tumor development [10]. Therefore, combination of TNF and another agent will be a promising method of treating malignant cells, if this agent can down-regulate the cell proliferation property of TNF. Therefore, novel reagents are necessary to inhibit TNF-induced survival signals, possibly by resulting in a synergistic effect on malignant cells.

When TNF binds to the TNF receptors, a group of signaling pathways were activated. For example, the caspase cascade can be activated through the Fas-associated death domain protein, which leads to apoptosis [10]. However, activation of the NF-κB pathway through the receptor-interaction protein upon binding of TNF facilitates cell survival and proliferation [11-13], which will decrease the anti-tumor apoptotic properties of TNF. Therefore, the balance of TNF-induced survival and death signaling is essential for the fates of cells in the presence of TNF.

During TNF-induced signaling, IκB kinases (IKKs), including IKKα, IKKβ, and IKKγ, are recruited to the signaling complex. The activated IKKβ then phosphorylates the NF-κB-bound IκB, which retain NF-κB in the cytoplasm, at their regulatory region to trigger their degradation. This process releases NF-κB to allow its translocation into the nucleus and activation of its target genes [14,15], with many of them possessing anti-apoptotic properties [16-18]. Since IKKβ has been identified as an Hsp90 client protein [19,20], we hypothesize that combined treatments with 17-DMAG and TNF may lead to a promising anti-tumor effects if 17-DMAG can decrease the survival signaling properties of TNF.

Since TNF and 17-DMAG may be useful for treating some types of malignancies. In this study, we have determined the effects of 17-DMAG and TNF treatments on multiple cell lines. It is found that the combined treatments result in synergistic killing of cells. It is also indicated that such a synergistic killing may be related to the decreases in IKKβ levels in the presence of 17-DMAG. Our results suggest that combination of 17-DMAG and TNF might be useful for treating malignancies upon further study in the further.

**Materials and methods**

**Cell lines and reagents**
The small cell lung cancer (SCLC) cell line (MS-1), the adenocarcinoma cell line (A549), the squamous-cell carcinoma cell line (LK-2), and the normal human bronchial epithelium cell line (NuLi-1) were provided by Shanghai Cell Biology Institute (China). These lung cancer cell lines were maintained in RPMI-1640 medium (Sigma-Aldrich Co. Ltd, Irvine, CA) supplemented with 10% fetal bovine serum (FBS), 1% L-glutamine, and 1% penicillin/streptomycin at 37°C with 5% CO2 and 100% humidity. 17-DMAG (InvivoGen, San Diego, CA) and TNF-α (TNF) were dissolved in DMSO. Recombinant Human TNF was purchased from Promega.

**Cell treatments and the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay**
Briefly, cells at a density of 1 × 10^5 cells/well were seeded into 6-well plates in RPMI-1640 supplemented with 10% calf serum and were cultured for 24 h. The cells were then treated with vehicle control (DMSO, 0.016%, v/v), TNF-α (10 ng/ml), 17-DMAG (0.05 μM), or TNF-α (10 ng/ml) plus 17-DMAG (0.05 μM). At the end of each experiment, cells were incubated with 0.5 mg/ml MTT for 4 h according to the protocol of manufacturer. Viability of treated cells was expressed relative to control cells (relative viability).

**Apoptosis assay**
Cells at a density of 1 × 10^5 cells/well were cultured in six-well plates in RPMI-1640 supplemented with 10% calf serum for 24 h, followed by addition of DMSO (0.016%, v/v), TNF (10 ng/ml), 17-DMAG (0.05 μM), or TNF (10 ng/ml) plus 17-DMAG (0.05 μM). After 48 h, cells were pelleted by centrifugation, washed once with PBS, fixed by incubation in 4% paraformaldehyde for 30 min at room temperature, and then washed again with PBS to remove the fixative. The fixed cells were resuspended in PBS that contained Hoescht 33258 (5 μg/ml), followed by an incubation at room temperature for 15 min in the dark. Aliquots of cells were placed on glass slides and examined for cells with apoptotic morphology (nuclear condensation and chromatin fragmentation) via fluorescence microscopy. To quantify the apoptosis, 300 nuclei from random microscopic fields were analyzed. Data are presented as the mean percentages of apoptotic cells.

**Immunoblotting assays**
Cells at a density of 1 × 10^5 cells/well were cultured in six-well plates in RPMI-1640 supplemented with 10% calf serum for 24 h, followed by addition of DMSO (0.016%, v/v), TNF (10 ng/ml), 17-DMAG (0.05 μM), or TNF (10 ng/ml) plus 17-DMAG (0.05 μM). After 48 h, cells were pelleted by centrifugation, washed twice with PBS. Total proteins were harvested from cells, separated on 10% SDS/PAGE gels, and then subjected to immunoblot analyses. The primary antibodies against IKKβ (about 90 kDa) and β-actin were purchased from Santa Cruz, USA (anti- IKKβ, cat# sc-8014, 1:200; anti-
β-actin, cat# sc-130301, 1:10,000). Secondary antibodies used in this study were goat anti-mouse IgG-HRP (Cat# sc-2005, 1:10,000, Santa Cruz, USA). Bound antibodies were detected using the ECL system (Pierce Biotechnology). The immunoblot experiments were repeated at least 3 times. The mean normalized optical density (OD) of HDAC protein bands relative to the OD of β-actin band from the same individual was calculated.

**Luciferase assays**
NuLi-1 cells, MS-1 cells, A549 cells, and LK-2 cells were plated onto 24-well plates and incubated for 20 h at 37°C in 5% CO2. The control pGL3 vector DNA (0.2 μg) (purchased from Clontech Co.) or similar amounts of Luciferase-NF-κB reporter vectors (Clontech Co., USA), was cotransfected into cells with the pRL-SV40 vector using the effectene transfection reagent (Qiagen, USA) for 20 h. Cells were then treated with DMSO (0.016%, v/v), TNF (10 ng/ml), 17-DMAG (0.05 μM), or TNF (10 ng/ml) plus 17-DMAG (0.05 μM) for 24 h. Luciferase activity was measured using the effectene transfection reagent (Qiagen, USA) according to the manufacturer’s protocol. The transcriptional activity of NF-κB in the cells transfected with the Luciferase-NF-κB reporter vectors were calculated as folds of those in the relative cells transfected with the empty vector.

**Statistical analyses**
The experimental data are expressed as mean ± SD. Statistical software (SPSS10.0) was used for independent sample t tests, followed by one-way variance analysis. In all analyses, P < 0.05 was considered statistically significant.

**Results**
TNF-α enhances the toxic effects on tumor cells of 17-DMAG
A normal human bronchial epithelium cell line (NuLi-1) and three lung cancer cell lines (MS-1, A549, and LK-2) were treated with TNF, 17-DMAG, or both of them together for 24 h or 48 h. The treatment with DMSO served as a drug vehicle control. The cells were analyzed for differences in cell killing upon various treatments via number counting of living cells in the presence or absence of the above compounds.

Results showed that the treatments with the drug vehicle control (DMSO) did not significantly affect cell viability of all of these four types of cells, including the normal human bronchial epithelium cell line (NuLi-1, Figure 1 Cell treatments with DMSO, TNF-α, 17-DMAG, or TNF-α and 17-DMAG together. The normal human bronchial epithelium cell line (NuLi-1) and three lung cancer cell lines (MS-1, A549, and LK-2) were treated with either vehicle control (DMSO), TNF-α (10 ng/ml), 17-DMAG (0.05 μM), or both. Cell counts in each condition were determined by trypan blue exclusion at the time points indicated. (A) NuLi-1 cells; (B) MS-1 cells; (C) A549 cells; (D) LK-2 cells. Cell viability was measured using 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay immediately before (day 0) and after 1, 2, or 3 days of incubation with the drugs. Values are means ± SD for three experiments. It is considered not significant, when P > 0.05 vs. control (DMSO) cell viability of each treatment. *, it is considered as a significant difference, when P < 0.05 vs. corresponding control.
Figure 1A) and three lung cancer cell lines MS-1 (Figure 1B), A549 (Figure 1C), and LK-2 (Figure 1D). Treatments with TNF-α had slight effects, if any, on cell viability of all of these four types of cells (Figure 1A-D). Treatments with 17-DMAG decreased viabilities of the three lung cancer cell lines MS-1 (Figure 1B), A549 (Figure 1C), and LK-2 (Figure 1D) by approximately 40% at day 2 and up to 60% at day 3, but no obvious decreases for the normal human bronchial epithelium cell line (NuLi-1, Figure 1A). When treated with TNF-α and 17-DMAG together, the viabilities of the three lung cancer cell lines MS-1 (Figure 1B), A549 (Figure 1C), and LK-2 (Figure 1D) were reduced by more than 80% at day 2 and by 90% at day 3. Combined treatments with TNF-α and 17-DMAG had not significantly decreased the viability of the normal cells (NuLi-1, Figure 1A), suggesting that such dosages of TNF-α and 17-DMAG are not toxic to normal cells. The above results suggest that TNF-α enhances the toxic effects on tumor cells of 17-DMAG.

TNF-α enhances the apoptosis induced by 17-DMAG

Since TNF-α enhances the toxic effects on tumor cells of 17-DMAG, it was determined that the effects of the drugs on apoptosis in all of these 4 types of cells. The cells were treated with either vehicle control (DMSO), TNF-α (10 ng/ml), 17-DMAG (0.05 μM), or both of TNF-α (10 ng/ml) and 17-DMAG (0.05 μM). To quantify the apoptotic incidence, we used a fluorescence microscopic assay following staining of the drug-treated cells with Hoescht 33258.

As shown in Figure 2, treatment with DMSO or TNF-α resulted in only slightly increased effects on apoptosis of all of these four types of cells. 17-DMAG caused apoptosis of MS-1, A549, and LK-2 cells with the incidences between 50-60%, although it did not alter the apoptotic incidence of the normal NuLi-1 cells significantly when compared with the DMSO treatment. It is worthy to note that the presence of TNF-α increased the 17-DMAG induced apoptosis, with the incidences up to 90% in comparison with the treatments with 17-DMAG alone. These results indicated that TNF significantly elevated the apoptosis induced by 17-DMAG, although it alone did not result in a significant induction of apoptosis.

17-DMAG treatments lead to degradation of IKKβ

IKKβ expression is reported to be reduced by Hsp90 inhibitors in some cell types. To determine if 17-DMAG inhibit the expression of IKKβ in NuLi-1, MS-1, A549, and LK-2 cells, the cells were treated with either vehicle control (DMSO), TNF-α (10 ng/ml), 17-DMAG (0.05 μM), or both of TNF-α (10 ng/ml) and 17-DMAG (0.05 μM). The total proteins were extracted and the expression levels of IKKβ were determined by using immunoblot analysis, with the cellular β-actin protein serving as a loading control. The mean normalized OD of IKKβ protein bands relative to the OD of β-actin band from the same condition was all calculated and subjected to statistical analyses.

Representative blots were shown in Figure 3. As shown in Figure 3, treatment with DMSO or TNF-α did not detectably affect IKKβ expression in all of these four types of cells. 17-DMAG, in the absence or presence of TNF-α, did not result in decreased expression of IKKβ in the normal NuLi-1 cells. However, the treatments with 17-DMAG decreased expression of IKKβ by up to 50%, 80%, and 90% in MS-1, A549, and LK-2 cells cells, respectively, according to the calculated OD values of the IKKβ bands relative to the β-actin bands. These results indicated that 17-DMAG significantly decreased...
IKKβ expression, although TNF-α did not affect such effect of 17-DMAG.

17-DMAG down-regulates the NF-κB transcriptional activity induced by TNF treatment

Next, we performed a luciferase reporter gene assay to determine whether TNF-α induces transcriptional activity of NF-κB and, if so, whether 17-DMAG affects the induction of NF-κB transcriptional activity by TNF-α. NuLi-1 cells, MS-1 cells, A549 cells, and LK-2 cells were transfected with a control pGL3 vector DNA or similar amounts of Luciferase-NF-κB reporter vectors together with the pRL-SV40 vector for 20 h.

As shown in Figure 4, treatments with TNF-α resulted in 3-fold higher luciferase activities in NuLi-1 cells and about 6-fold higher luciferase activities in MS-1 cells, A549 cells, and LK-2 cells, when compared with the DMSO conditions. Treatments with 17-DMAG did not lead to detectable alteration of the luciferase activities in NuLi-1 cells, but reduced the luciferase activities in MS-.
1 cells, A549 cells, and LK-2 cells by about 70% in comparison with TNF-α and 17-DMAG together, the luciferase activities in NuLi-1 cells were not significantly changed, but the activities in MS-1 cells, A549 cells, and LK-2 cells were reduced by about 70-80%, in comparison with the DMSO conditions. These results indicated that 17-DMAG down-regulates the NF-κB transcriptional activity induced by TNF treatment.

**Discussion**

Since many Hsp90 clients are important for disease development, 17-DMAG is extensively studied for possible treatments of various diseases [21-25]. In this study, we have determined the effects of 17-DMAG and TNF treatments on multiple cell lines. It is found that the combined treatments result in synergistic killing of malignant cells. It is also indicated that such a synergistic killing may be related to the decreases in IKKβ levels in the presence of 17-DMAG. Our results suggest that combination of 17-DMAG and TNF might be useful for treating malignancies upon further study in the future.

Combined treatments with TNF-α and 17-DMAG had not significantly decreased the viability of the normal NuLi-1 cells, but leads to obvious toxicity on malignant MS-1, A549, and LK-2 cells. This result may be related to the properties of Hsp90. As one of the most abundant proteins in the cytoplasm, Hsp90 constitutes approximately 1-2% of the total proteins [26], although some Hsp90 may translocate to the nucleus in response to stress and other environmental stimuli [27-30]. Under normal conditions of the normal cells, there is an abundant Hsp90 chaperone reservoir, which can buffer proteostasis against environmental stress. However, under extreme environmental conditions, such as conditions in malignant cells, the chaperone reservoir is rapidly exhausted. Therefore, effects of 17-DMAG may be increased correspondingly. In the other words, function of Hsp90 inhibitors can then affect the relationship between genotype and phenotype, and thus influencing human health, disease and evolutionary processes. This reason also explains why 17-DMAG did not affect IKKβ expression in normal cell.

Hsp90 is composed of a highly conserved amino-terminal domain, a middle domain, followed by a carboxy-terminal domain [31]. Hsp90 binds ATP in its amino-terminal domain, hydrolyzing it upon interaction with clients and co-chaperoning molecules. Structurally unrelated inhibitors of Hsp90, such as 17-DMAG, replace ATP and specifically destroy Hsp90 function [32]. The strong conservation of the ATP-binding pocket allows 17-DMAG to serve as extremely useful and specific tools for affecting HSP90 function. This may explain why TNF did not enhance the effect of 17-DMAG on IKKβ expression, while they exert a combined effect on viability of malignant MS-1, A549, and LK-2 cells, possibly by playing roles in different cellular signaling pathways or processes.

When cells are treated with TNF, NF-κB is activated through RIP-mediated activation of IκB kinase (IKK) and then released, allowing for its translocation into the nucleus and activation of its target genes [14]. Many cellular targets of NF-κB, such as Bcl-xL, cIAP-1, A20, cIAP-2, and XIAP, have anti-apoptotic functions [16-18]. Therefore, many kinds of tumor cells are resistant or tolerant to TNF-induced apoptosis, although TNF may lead to apoptosis via the FADD-caspase pathway and the TRAF2-JNK2 pathway. The NF-κB activity is considered as a major factor of TNF resistance in cancer cells [33]. Our results clearly show that inhibition of the NF-κB pathway by 17-DMAG significantly sensitizes the TNF-treated cells to induced cell death, supporting the combined effects of 17-DMAG and TNF on cells through a mechanism related to the NF-κB pathway. In addition to the small-molecule compounds such as 17-DMAG, the siRNA strategies are often used to treat tumor cells. It is found that targeting the fascin pathway by using a specific siRNA might be a novel therapeutic strategy for curing the esophageal squamous cell carcinoma [34]. Compounds can be also used for study of gene expression. It has been reported that gene expression profile test is useful to resolve the lung squamous cancers and other cancers such as the head and neck squamous carcinoma [35].

**Competing interests**

The authors declare that they have no competing interests.

**Authors’ contributions**

ZQ and HD designed the experiments, analyzed the data, and wrote the manuscript. XX, WF, and XY did the experiments and analyzed the data. All authors read and approved the final manuscript.

**Acknowledgements**

This work was supported by the following grants: Shandong province tackle key problems in science and technology program (grant NO. Y2006C14) and Qingdao municipal science and technology commission (grant No. 05-1-NS-74).

Received: 7 January 2013 Accepted: 22 April 2013

Published: 1 May 2013

**References**

1. Prodromou C, Roe SM, O’Brien R, Ladbury JE, Piper PW, Pearl LH: Identification and structural characterization of the ATP/ADP-binding site in the Hsp90 molecular chaperone. Cell 1997, 90:65–75.

2. da Silva VC, Ramos CH: The network interaction of the human cytosolic 90 kDa heat shock protein Hsp90: A target for cancer therapeutics. J Proteomics 2012, 75:2790–2802.

3. Taipale M, Jarosz DF, Lindquist S: Hsp90 at the hub of protein homeostasis: emerging mechanistic insights. Nat Rev Mol Cell Biol 2010, 11:515–528.

4. Theodoraki MA, Caplan AJ: Quality control and fate determination of Hsp90 client proteins. Biochim Biophys Acta 1923, 2012:683–688.

5. Hoppie J, Windhagen A, Vehvauer G: Hsp90: a drug target? Curr Oncol Rep 2010, 12:95–101.
6. Pacey S, Banerji U, Judson I, Workman P: Hsp90 inhibitors in the clinic. \hspace{1em} Handb Exp Pharmacol 2006, 172:331–358.

7. Neckers L, Ivy SP: Heat shock protein 90. \hspace{1em} Curr Opin Oncol 2003, 15:419–424.

8. Kamal A, Thao L, Semintafar J, Zhang L, Boehm MF, Fritz LC, Burrows FJ: A high-affinity conformation of Hsp90 confers tumour selectivity on Hsp90 inhibitors. \hspace{1em} Nature 2002, 415:407–410.

9. Aggarwal BB: Signaling pathways of the TNF superfamily: a double-edged sword. \hspace{1em} Nat Rev Immunol 2003, 3:745–756.

10. Wajant H, Pfizenmaier K, Scheurich P: Tumor necrosis factor signaling. \hspace{1em} Cell Death Differ 2003, 10:45–65.

11. Kelliher MA, Grimm S, Ihdha Y, Kuo F, Stanger BZ, Leder P: The death domain kinase RIP mediates the TNF-induced NF-κB signal. \hspace{1em} Immunity 1998, 8:297–303.

12. Ting AT, Pimentel-Munoz FX, Seed B: RIP mediates tumor necrosis factor receptor 1 activation of NF-κB but not Fas/APO-1-initiated apoptosis. \hspace{1em} EMBO J 1996, 15:6189–6196.

13. Zhang J, Winoto A: A mouse Fas-associated protein with homology to the human MORT/FADD protein is essential for Fas-induced apoptosis. \hspace{1em} Mol Cell Biol 1996, 16:2756–2763.

14. Karin M, Yamamoto Y, Wang QM: The IKK NF-κB system: a treasure trove for drug development. \hspace{1em} Nat Rev Drug Discov 2004, 3:17–26.

15. Yang J, Lin Y, Guo Z: The essential role of MEKK3 in TNF-induced NFκB activation. \hspace{1em} Nat Immunol 2001, 2:620–624.

16. Wu MX, Ao Z, Prasad KV, Wu R, Schlossman SF: IEX-1L, an apoptosis inhibitor involved in NF-κB-mediated cell survival. \hspace{1em} Science 1998, 281:998–1003.

17. Wang CY, Mayo MW, Korneluk RG, Goeddel DV, Baldwin AS: NFκB antipapoptotic induction of TRAF1 and TRAF2 and c-IAP1 and c-IAP2 to suppress caspase-8 activation. \hspace{1em} Science 1998, 281:1680–1683.

18. Kamata H, Honda S, Maeda S, Chang L, Hirata H, Karin M: Reactive oxygen species promote TNFα-induced death and sustained JNK activation by inhibiting MAP kinase phosphatases. \hspace{1em} Cell 2005, 120:649–661.

19. Broemer M, Krapmann D, Scheiderer C: Requirement of Hsp90 activity for lkb kinase (IKK) biosynthesis and for constitutive and inducible IKK and NFκB activation. \hspace{1em} Oncogene 2004, 23:5378–5385.

20. Lewis J, Devin A, Miller A: Disruption of hsp90 function results in degradation of the death domain kinase, receptor-interacting protein (RIP), and blockage of tumor necrosis factor-induced nuclear factor-kB activation. \hspace{1em} J Biol Chem 2000, 275:10519–10526.

21. Fukushima R, Kang KJ: Geldanamycin analog 17-DMAG limits apoptosis in human peripheral blood cells by inhibition of p53 activation and its interaction with heat-shock protein 90 kDa after exposure to ionizing radiation. \hspace{1em} Radiat Res 2011, 176:333–345.

22. Lancer JE, Gojo I, Burton M: Phase I study of the heat shock protein 90 inhibitor alvespimycin (KOS-1022, 17-DMAG) administered intravenously twice weekly to patients with acute myeloid leukemia. \hspace{1em} Leukemia 2010, 24:669–705.

23. Jhaveri K, Miller K, Rosen L: A Phase I Dose-Escalation Trial of Trastuzumab in Her2-positive Advanced Breast Cancer. \hspace{1em} Breast Cancer Res Treat 2004, 84:194–203.

24. Palacios C, Martín-Pérez R, López-Pérez AI, Pandiella A, López-Rivas A: Autophagy inhibition sensitizes multiple myeloma cells to 17-DEA. \hspace{1em} Leuk Res 2013, 37:229–235.

25. Zheng N, Zou P, Wang S, Sun D: In vitro metabolism of 17-deacetoxycholanic acid-17-deacetylgalectosaminyl in human liver microsomes. \hspace{1em} Drug Metab Dosepos 2011, 39:627–635.

26. Borkovich KA, Farewell FW, Finkelstein DB, Taullien J, Lindquist S: Hsp82 is an essential protein that is required in higher concentrations for growth of cells at higher temperatures. \hspace{1em} Mol Cell Biol 1989, 9:3919–3930.

27. Akers G, Mosberg K, Sundqvist KG, Gustafsson JA, Wikstrom AC: Evidence for reversible, non-microtubule and non-microfilament-dependent nuclear translocation of hsp90 after heat shock in human fibroblasts. \hspace{1em} Eur J Cell Biol 1992, 58:356–364.

28. Biggiero M, Tanguay RM, Marin R, Wu Y, Martin TE, Fakan S: Localization of heat shock proteins in mouse male germ cells: an immunoelectron microscopic study. \hspace{1em} Exp Cell Res 1996, 229:77–85.

29. Langer T, Rosmus S, Fasold H: Intracellular localization of the 90 kDa heat shock protein (HSP90α) determined by expression of a EGFP-HSP90α-fusion protein in unstressed and heat stressed 3T3 cells. \hspace{1em} Cell Biol Int 2003, 27:47–52.

30. Pratt WB, Toft DO: Steroid receptor interactions with heat shock protein and immunophilin chaperones. \hspace{1em} Endocr Rev 1997, 18:306–360.

31. Pearl LH, Prodomou C: Structure and mechanism of the Hsp90 molecular chaperone machinery. \hspace{1em} Annu Rev Biochem 2006, 75:271–294.

32. Whitesell L, Lindquist S: HSP90 and the chaperoning of cancer. \hspace{1em} Nature Rev Cancer 2005, 5:561–712.

33. Keane MM, Rubinstein Y, Cuello M: Inhibition of NF-κB activity enhances TRAIL mediated apoptosis in breast cancer cell lines. \hspace{1em} Breast Cancer Res Treat 2000, 64:211–219.

34. Ortiz CM, Ito T, Hashimoto Y, Nagayama S, Iwai A, Tsuonoda S: Effects of small interfering RNAs targeting Fas on human esophageal squamous cell carcinoma cell lines. \hspace{1em} Diagn Pathol 2010, 5:41.

35. LaI, Panos R, Marjanovic M, Walker M, Fuentes E, Kubicek GJ: A gene expression profile test to resolve head & neck squamous versus lung squamous cancers. \hspace{1em} Diagn Pathol 2013, 8:44.

Cite this article as: Qu et al.: Combined effects of 17-DMAG and TNF on cells through a mechanism related to the NF-κappaB pathway. \hspace{1em} Diagnostic Pathology 2013 8:70.

Submit your next manuscript to BioMed Central and take full advantage of:

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

Submit your manuscript at www.biomedcentral.com/submit